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Objectives: To investigated whether the CTX-M-14 gene could be transferred
from a clinical Shigella sonnei strain to commensal Escherichia coli strain in the
gastroenteritis microbiome.
Methods: E. coli strains were isolated from 30 stool samples of S. sonnei infected
students in a gastroenteritis outbreak in 2004 and were characterized by anti-
biotic resistance analysis, in vitro conjugation and in vivo transfer of CTX-M-14
gene and molecular assays.
Results: One strain of Escherichia coli that had high levels of resistance to
cefotaxime was isolated from a patient infected with S. sonnei. Isoelectric
focusing showed that the E. coli and S. sonnei strains produced a b-lactamase
with an isoelectric point of 8.1. Moreover, polymerase chain reaction analysis
indicated that both strains possessed the same DNA sequences for CTX-M-14. The
results of in vitro and in vivo conjugation showed that the efficiency of CTX-M-14
transfer from S. sonnei to E. coli was similar to CTX-M-14 transfer between E. coli
strains.
Conclusion: The data suggest that the acquisition of the extended-spectrum b-
lactamases gene by pathogenic bacteria in the human intestinal tract to
commensal microbiome bacteria can cause serious infectious diseases.1. Introduction
Antimicrobial resistance has become a global public
health problem, which is caused by the over use of an-
tibiotics [1e4]. Numerous studies have been published
that describe the epidemiology and molecularted under the terms of the
) which permits unrestrict
operly cited.
ase Control and Preventioncharacterization of the extended-spectrum b-lactamases
(ESBLs) [5,6].
In the Enterobacteriaceae, resistance to ampicillin is
mainly due to ESBLs such as TEM-1 and SHV-1 enzymes
that hydrolytically cleave the b-lactam ring [7]. However,
CTX-M-typeESBLs have recently acquired amajor role asCreative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
. Published by Elsevier Korea LLC. All rights reserved.
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cephalosporins in Enterobacteriaceae [8]. In some epide-
miological settings the prevalence of CTX-M-type en-
zymes can be even higher than that of the TEM- or SHV-
type ESBL variants [9e12]. At present, the CTX-M fam-
ily comprises >50 enzymes that have greater hydrolytic
activity against cefotaxime than ceftazidime and can be
subclassified to five major groups [8]. Escherichia coli is
the first species in which CTX-M-type enzymes were
identified as acquired ESBLs [13]. Dissemination of CTX-
M-type enzymes inKlebsiella pneumoniae and Salmonella
enterica has increasingly been reported [10,14,15].
In Korea, CTX-M-type enzymes have also been
observed; for example, CTX-M-14 in a Shigella sonnei
strain isolated during an outbreak of gastroenteritis in 2000
and CTX-M-12 from three clinical E. coli isolates [16,17].
The dissemination of ESBL may be due to the hori-
zontal transfer of resistance plasmids. However, little is
known about the transfer interspecies. In this study, to
investigate the possible transfer of resistance plasmids,
we have isolated fecal Escherichia coli strains from the
patient infected with S. sonnei during an outbreak of
gastroenteritis in 2004 and performed in vivo-transfer of
the CTX-M-14 gene in a mouse model between the
isolated fecal Escherichia coli strains and the clinical S.
sonnei strain from a patient.2. Materials and methods
2.1. Bacterial strains
For the test of antibiotic resistance in this study,
150 E. coli strains were isolated from 30 students of
Chungju Elementary School in Korea (Table 1), who
had visited hospital during a gastroenteritis outbreak in
2004. They were patients who had been infected by S.
sonnei. E. coli BL21(DE3) was the host for cloning
experiments. E. coli J53 AzideR and E. coli ATCC
25933 were used as a recipient strain for conjugative
transfer and a minimal inhibitory concentration (MIC)
reference strain, respectively.
2.2. Antimicrobial susceptibility testing
Antibiotic susceptibility of the isolates was tested by
the disk diffusion method on MuellereHinton agar
(bioMe´rieux, Marcy l’Etoile, France) and agar dilution
methods according to the recommendations of theTable 1. Information of collected stool samples from
students in an outbreak in 2004
Age groups
Patients with dysentery
TotalMale Female
12y 13 13 26
13y 2 2 4
Total 15 15 30Clinical and Laboratory Standards Institute [18]. The
following antibiotics were tested: ampicillin/sulbactam,
ampicillin, piperacillin/tazobactam, cephalothin, cefox-
itin, cefotetan, cefotaxime, cefepime, tobramycin,
gentamicin, amikacin, netilmicin, tetracycline, aztreo-
nam, trimethoprim/sulfamethoxazole, and imipenem. E.
coli ATCC 25922 and E. coli ATCC 35218 were used as
quality controls. MICs of b-lactams were determined
alone or in combination with a fixed concentration of
clavulanic acid (4 mg/L).
2.3. Isoelectric focusing
To determine the isoelectric point (pI), 5 mL of the
condensed supernatant containing b-lactamase was
loaded onto a Novex IEF Gel (pH 3e10; Invitrogen,
Carlsbad, CA, USA) with an Xcell Surelock Mini-Cell
system (Invitrogen). Running conditions were 100 V
constant for 1 hour, 200 V constant for 1 hour, and
500 V for 30 minutes. The pI of the b-lactamase was
measured by staining the gel with a 0.05% solution of
nitrocefin (Oxoid, Basingstoke, UK).
2.4. Polymerase chain reaction
Searches for genes coding for ESBLs were performed
by polymerase chain reaction (PCR) amplification with
the specific primers as followed: blaTEM-gene (F-
ATGAGTATTCAACATTTCCG and R-CTGA-
CAGTTACCAATGCTTA), blaSHV-gene (F-
GGGTTATTCTTATTTGTCGC and R-
TTAGCGTTGCCAGTGCTC) and blaCTX-M-gene (F-
TTTGCGATGTGCAGTACCAGTAA and R-CGA-
TATCGTTGGTGGTGCCATA). The templates for
PCR amplification in clinical isolates were a whole-cell
lysate. The PCR products were subjected to direct
sequencing. Both strands of each PCR product were
sequenced twice with an automatic sequencer (model
373A; Applied Biosystems, Weiterstadt, Germany).
2.5. In vitro filter mating
Conjugation experiments were performed by the filter
mating procedure as follows. Donor (ESBL Shigella
sonnei isolate) and recipient (E. coli J53 Azir) strains
were grown with shaking in braineheart infusion (BHI;
bioMe´rieux) broth for 6 hours at 37C, then 100 mL of
the donor and the recipient strains were spread onto a
0.45 mm (pore size) nitrocellulose membrane filter
(Millipore, Saint-Quentin, France) placed on top of BHI
agar (bioMe´rieux). After 18 hours of incubation at 37C,
the cells were suspended in broth, diluted in sterile water
supplemented with peptone in 10-fold series, and
100 mL of each dilution were plated on selective
medium.
2.6. In vivo conjugation
For the in vivo conjugation, germ-free consanguin-
eous C3H mice (mean weight, 25 g) were used. The
germ-free mouse received the recipient strain E. coli J53
Figure 1. Antibiotic resistance patterns of Escherichia coli strains isolated from Shigella sonnei infected students in a gastro-
enteritis outbreak in 2004.
158 S.-H. Cho, et alAzir [100 colony-forming-units (CFU)] and donor strain
S. sonnei (20 CFU). Two types of transfer, i.e., CTX-M-
14 gene transfer from ESBL S. sonnei isolate to E. coli
J53 Azir and CTX-M-14 gene transfer from ESBL E.
coli isolate to E. coli J53 Azir, were studied in this
model. Fecal samples were collected from the mice in
1 week following the inoculation of the donor strain,
then once/week for 3 weeks. Ten-fold dilutions were
made in 0.85% saline and cultivated on CTX-M media.
Bacterial counts were expressed as log (CFU) of feces.
3. Results
3.1. Characterization of antibiotic resistance
and ESBL of E. coli strain isolated from a
patient of ESBL S. sonnei outbreak
In total, 150 E. coli strains were isolated from 30
stool samples of S. sonnei infected students in a
gastroenteritis outbreak in 2004. For the test of antibi-
otic resistance of the E. coli strains, agar dilution
methods were used. The isolates showed high antibioticFigure 2. Bacterial counts in the feces of mresistance to ampicillin (36.7%), cephalothin (26.7%),
tetracycline (40%), and trimethoprim/sulfamethoxazole
(23.3%). However, among the isolates, no resistance to
netilmicin or aztreonam was found (Figure 1).
One strain of E. coli was isolated from a student also
had a high level of cefotaxime resistance similar to S.
sonnei strains isolated from an outbreak in 2004. MIC
analysis of both E. coli and S. sonnei strains showed
resistant phenotype to ampicillin, ticarcillin, cefotaxime,
cephalothin, nalidixic acid, and trimethoprim/sulfa-
methoxazole, but sensible phenotype to cefoxitin and
ciprofloxacin. PCR amplifications using primers specific
for ESBL-encoding genes revealed that bothE. coli and S.
sonnei isolates possessed both blaTEM and blaCTX-M-type
genes, whereas no blaSHV genes were detected in any of
the isolates. Sequences of the blaTEM PCR amplicons
were 100% identical to the blaTEM-1 sequence.
Sequence data from the amplicons of the CTX-M-1
cluster indicated the presence of CTX-M-14. The ge-
netic organization of the CTX-M-14 gene was investi-
gated by sequencing of the regions surrounding this gene.ice in in vivo conjugation experiments.
CTX-M-14 gene transfer 159Isoelectric focusing of the partially purified b-lactamase
ofE. coliBL21 (DE3) carrying plasmid pET30a-CTX-M-
14 revealed a band with a pI value of 8.1.
3.2. Possibility of CTX-M-14 gene transfer from
ESBL S. sonnei to E. coli in gastroenteritis
microbiome
To confirm the possibility of transfer of CTX-M-14
from ESBL S. sonnei isolate to E. coli in gastroenteritis
microbiome, we performed in vitro conjugation and
in vivo transfer of CTX-M-14 gene in a mouse model
between the ESBL S. sonnei strain and E. coli strains.
Cefotaxime resistance was transferred from ESBL S.
sonnei to E. coli J53 Azir at the similar frequency as
conjugation between the ESBL E. coli and E. coli J53
Azir in vitro conjugation and in vivo transfer (Figure 2).
Transconjugants were detected in 1 week of inoculation
with the donor strain, and persisted throughout the
experiment. On Day 21, bacterial counts in the whole
intestinal tract were similar to those found in fecal
samples. PCR analysis of the transconjugants obtained
in vivo showed that donor strain and transconjugants
harbored CTX-M-14 gene. The transconjugants were
found to be resistant to cefotaxime.4. Discussion
In Korea, the rate of ESBL-producing Enter-
obacteriaceae has increased recently [19]. Several re-
ports have shown that CTX-M-producing E. coli isolates
are important causes of bloodstream infections, with the
urinary tract as the most frequent infection site [20e22].
Our study described for the first time the possibility of
the in vivo transfer of cefotaxime resistance from ESBL
S. sonnei to E. coli in gastroenteritis microbiome. In vivo
experiments revealed that the efficiency of CTX-M-14
transfer from S. sonnei to E. coli was similar to CTX-
M-14 transfer between E. coli strains. Our model
showed the risk of acquisition of the CTX-M-14 gene by
pathogenic bacteria in the human intestinal tract to
commensal microbiome bacteria. This transfer may
occur, leading to the formation of a dangerous pool of
ESBL E. coli capable of transmitting their resistance
gene to other species. These data suggest that bacteria
colonizing healthy individuals constitute a reservoir of
new or known ESBL genes that could further evolve in
the nosocomial setting and be responsible for future
epidemic situations. Therefore, ongoing surveillance
and investigations for the dynamic and fast evolving
ESBL genes in intestine are needed.Conflicts of interest
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